P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease

By  

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6169-6180

Bentham Science Publishers

Access to resources Recommend Favorite

P2Y 11 receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors

By Conigrave A.D.   Fernando K.C.   Gu B.   Tasevski V.   Zhang W.   Luttrell B.M.   Wiley J.S.  

European Journal of Pharmacology, Vol. 426, Iss. 3, 2001-08 ,pp. : 157-163

Elsevier

Access to resources Recommend Favorite

Purinoceptors (P2X-receptor isoforms)

By Zidek W.   Tepel M.   Schluter H.   van der Giet M.   Jankowski J.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 101-103

Informa Healthcare

Access to resources Recommend Favorite

Protein kinase C &unknown;-dependent pathway of extracellular signal-regulated protein kinase activation by P2Y 1 and P2Y 2 purinoceptors that activate cytosolic phospholipase A 2 in endothelial cells

By Chen B.-C.   Lin L.-L.   Lin W.-W.  

European Journal of Pharmacology, Vol. 373, Iss. 1, 1999-05 ,pp. : 101-110

Elsevier

Access to resources Recommend Favorite

No requirement of P2X1 purinoceptors for platelet aggregation

By Takano S.   Kimura J.   Matsuoka I.   Ono T.  

European Journal of Pharmacology, Vol. 372, Iss. 3, 1999-05 ,pp. : 305-309

Elsevier

Access to resources Recommend Favorite